Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
Résumé
Background: A standard of care for pretreated, advanced non-small-cell lung cancers (NSCLCs), nivolumab has demonstrated long-term benefit when administered for 2 years. We aimed to better discern an optimized administration duration by retrospectively analyzing real-life long-term efficacy in a prospective cohort. Methods: All nivolumab-treated adults with advanced NSCLCs (01/09/2015 to This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Domaines
Cancer| Origine | Fichiers éditeurs autorisés sur une archive ouverte |
|---|